Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 3954
MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.
MDV3100, a new generation of oral anti-androgen, which shows different pharmacological profiles from current anti-androgens, has been shown in preclinical studies to provide more complete suppression of the androgen receptor pathway than bicalutamide, the most commonly used anti-androgen. MDV3100 slows growth and induces cell death in bicalutamide-resistant cancers via three complementary actions – MDV3100 blocks testosterone binding to the androgen receptor, impedes movement of the androgen receptor to the nucleus of prostate cancer cells (nuclear translocation), and inhibits binding to DNA. Preclinical data published in Science earlier this year demonstrated that MDV3100 is superior to bicalutamide in each of these three actions.
IPSCIO Record ID: 3516
Subject to the terms and conditions of this Agreement, the Licensee hereby grants the Licensor a non-exclusive, non-sub-licensable solely to permit subcontractors to perform Licensor's assigned responsibilities under any Joint Development Plan, Joint Manufacturing Plan, Joint Medical Affairs Plan or Joint Commercialization Plan, royalty-free, fully-paid license under the Technology, and sub-license under the Licensor Technology and UCLA Technology licensed to the Licensee.
IPSCIO Record ID: 27588
The Licensee had administered galeterone to over 250 prostate cancer patients and healthy volunteers in Phase I and Phase II clinical trials. The plans for a Phase III clinical trial are for the first half of 2015.
IPSCIO Record ID: 1617
IPSCIO Record ID: 2928
IPSCIO Record ID: 369284
Licensed Patent means (a) U.S. Provisional Patent Application Nos. 62/041,368, 61/124,359. 61/124,328, 61/114,153 International Patent Application No. PCT/US2009/02392 U.S. Patent Application No. 12/988,299, Canadian Patent Application No. 2,721,506 and European Patent Application No. 09733012.0 and the inventions disclosed and claimed therein
Technology related to the development of a companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with the Companyâ€™s lead product, galeterone, which is in development for the treatment of AR-V7 positive metastatic CRPC.
Galeterone is a highly selective, multi-targeted, oral small molecule drug candidate that has advantages over existing prostate cancer therapies. Galeterone acts by disrupting the androgen receptor signaling pathway, which is the primary pathway that drives prostate cancer growth. The pathway is ordinarily activated by the binding of male hormones, or androgens, such as testosterone and the more potent androgen dihydrotestosterone, or DHT, to the ligand binding domain of androgen receptors in prostate cancer cells. Galeterone disrupts the activation of the pathway through multiple mechanisms of action.
Field of Use companion diagnostic for Galeterone (excluding commercial sale as research reagent).
IPSCIO Record ID: 26125
IPSCIO Record ID: 26022
The Parties have agreed to resolve Litigation pursuant to a Settlement Agreement of even date herewith, pursuant to which the Parties have agreed, among other things, that Licensor will agree that regorafenib is not a Collaboration Compound under the Collaboration Agreement, and Licensee will grant Licensor certain rights related to the development and promotion of regorafenib, and pay Licensor royalties based on the sales of regorafenib together with fees for co-promotion services.
Pursuant to this agreement regarding Regorafenib, Licensor grants an exclusive, worldwide license, with the right to grant sublicenses, under the Licensor Developed IP developed pursuant to the Separate Development Program which resulted in the approval for such Separate Indication to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import and have imported, the Product for all indications.
This agreement includes non-exclusive grants back to Licensor.
These agreements also settle and dismiss all claims related to the lawsuit.
Compound means the compound designated as regorafenib, also referred to as BAY 73-4506, together with salts and esters thereof or any other modification which would permit the use of clinical data for regorafenib to be used to establish the efficacy of the modified molecule.
Nexavar, an oral therapy for liver cancer and the treatment of patients with advanced kidney cancer, is currently approved in more than 100 countries worldwide. It is also being evaluated in other cancers by Bayer, Onyx and other parties.
IPSCIO Record ID: 203444
– to Develop, have Developed, make, have made, and use the Licensed Compound and Licensed Product in the Field, and
– to sell, offer for sale, register, Commercialize and otherwise exploit the Licensed Product in the Field; provided that notwithstanding the exclusive rights granted to Licensee in the foregoing grant, Licensor shall retain the limited right to use the Licensor Intellectual Property to the extent necessary to perform its express obligations under this Agreement, including the Clinical Development Plan, to conduct the Licensor Clinical Studies, subject to the approval of the Joint Steering Committee, and as otherwise agreed to in writing by the Parties.
The exclusivity of the sublicense granted under such Licensor Intellectual Property is subject to the applicable non-exclusivity terms in the another Agreement.
Included with this agreement is also a non-exclusive, non-sublicensable, except to subcontractors as permitted under this Agreement, solely to permit such subcontractors to perform Licensors assigned responsibilities under the Clinical Development Plan, royalty-free, fully-paid right and license, by Licensee to Licensor under the Licensee Know-How and Licensee Patent Rights, solely to the extent necessary to conduct the activities assigned to Licensor by the Joint Steering Committee under the Clinical Development Plan.
TRPM-2 Antisense Therapy;
TRPM-2 Antisense Therapy and Combination composition;
TRPM-2 Antisense Therapy Using ai Oligonucleotide Having 2-0-(2- Methoxy)Ethyl Modifications Compound;
Chemo-and radiation-sensitization or cancer by antisense TRPM-2 oligodcoxynucleotides;
Treatment of Melanoma by Reduction in Clusterin Levels;
Clusterin antisense therapy for treatment of cancer;
Treatment of Cancer By Perturbation of Clusterin Levels;
Human Type 2 RNASE H;
Gapped Oligonucleotides, Directed to Gapmer and Hemimer Compounds with 2-O-ALKYL modifications;
2-O-Modified Nucleosides and Phosphoramidites; and others.
The collaboration agreement is for developing and commercializing OGX-011. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance. OGX-011 is expected to be used as adjunct therapy to enhance the effectiveness of chemotherapy and has shown promising results when added to currently available chemotherapies in several tumor types addressing a significant unmet medical need.
IPSCIO Record ID: 4661
IPSCIO Record ID: 245947
US Patent Number / Application 60/571,149
MDR Inhibitors which are the subject of the Patent Rights ('Invention').
Panacela Product shall mean the following Products developed and commercialized by Panacella
(i) Arkil small-molecular polycyclic organic compound for systemic use to treat hormone-independent prostate tumors;
(ii) Mobilan recombinant adenovirus of CBLB501 series for localized intratumor injection, converts the injected tumor into an efficient vaccine in situ by intratumor expression of a bacterial immunogen and its receptor; and
(iii) Revercom nano-particle combining a chemotherapeutic drug with an inhibitor of the tumor drug resistance molecular mechanism of CBLC500 series for the treatment of tumors resistant to chemotherapy.
Foundation Technology shall mean all Foundationâ€™s and Other Institutionâ€™s unpatented inventions, know-how, trade secrets, analysis, discoveries, techniques, methods, clinical and other data, and other intellectual property relating to the research of Doctor or arising out of or in direct connection with work of Doctor in the field of regulating cell death (i) curing cancer treatment side effects by differential modulation cell death / survival mechanisms uniquely deregulated in cancer cells; (ii) selective sensitization of cancer cells to treatment by using the same approach; (iii) using anti-apoptotic proteins secreted by microbial parasites to cure tissue damage associated with cancer treatment, inflammation and other pathologies (stroke, heart attack).